Hairy Cell Leukemia: Clinical Trials

11 trials for Hairy Cell Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 completed, 1 active not recruiting, 1 not yet recruiting. 11 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Recruiting 4, Completed 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 23Completed 2, Recruiting 1

Follow Hairy Cell Leukemia: new trials by email Literature Review of Hairy Cell Leukemia trials Research Report on Hairy Cell Leukemia

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Phase 1Not yet recruitingLuminary Therapeutics272026-09-012026-07-01
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma
Phase 1RecruitingStanford University1482024-03-292026-08-12
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
CD22CART cell infusion - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 1RecruitingNational Cancer Institute (NCI)272022-05-232026-10-16
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia
Phase 1RecruitingNewave Pharmaceutical Inc602021-07-192026-02-13
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia
Phase 1Active not recruitingNational Cancer Institute (NCI)182019-10-032026-06-29
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia
Phase 1 / Phase 2CompletedAlexey Danilov, MD242017-07-172023-08-08
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL
Phase 1 / Phase 2CompletedAcerta Pharma BV1612015-02-202026-05-13
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
PLX8394 - Melanoma, Thyroid Cancer
Phase 1TerminatedFore Biotherapeutics52014-02-012020-10-19
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox) - Hairy Cell Leukemia
Phase 1CompletedMedImmune LLC492007-05-102019-04-02
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Hairy Cell Leukemia
Phase 1UnknownCambridge Antibody Technology402007-04-012007-04-18

Narrower conditions

Leukemia, Hairy Cell (11)  ·  Lymphoma, Follicular (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Waldenstrom Macroglobulinemia (3)  ·  Burkitt Lymphoma (2)  ·  Leukemia (2)  ·  Lymphoma (2)  ·  Multiple Myeloma (2)  ·  Recurrence (2)  ·  Anemia (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)

Broader conditions

Hematologic Diseases (11)  ·  Hemic and Lymphatic Diseases (11)  ·  Immune System Diseases (11)  ·  Immunoproliferative Disorders (11)  ·  Lymphatic Diseases (11)  ·  Lymphoproliferative Disorders (11)  ·  Neoplasms (11)  ·  Neoplasms by Histologic Type (11)  ·  Leukemia (9)  ·  Disease Attributes (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Blood Protein Disorders (4)  ·  Cardiovascular Diseases (4)  ·  Hemorrhagic Disorders (4)

Interventions

immunotoxin HA22 (3)  ·  Rituximab (2)  ·  6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)  ·  Acetaminophen (1)  ·  Aspirin (1)  ·  Biological Therapy (1)  ·  Biopsy (1)  ·  CT-P10 (1)  ·  Calcium Dobesilate (1)  ·  Cladribine (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Famotidine (1)  ·  PLX8394 (1)  ·  Specimen Handling (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Acerta Pharma BV (1)  ·  Alexey Danilov, MD (1)  ·  Cambridge Antibody Technology (1)  ·  Fore Biotherapeutics (1)  ·  Luminary Therapeutics (1)  ·  MedImmune LLC (1)  ·  Newave Pharmaceutical Inc (1)  ·  Stanford University (1)

Countries

United States (11)  ·  Poland (2)  ·  United Kingdom (1)

Top investigators

Robert J Kreitman, M.D. (2)  ·  Craig Okada, M.D. (1)  ·  Matthew Frank, MD, PhD (1)  ·  Seema A Bhat (1)  ·  Sunil Sharma, MD (1)

Results publications

PMID 41980020, PMID 18596230, PMID 22355053, PMID 29487070, PMID 34196037

NIH funding

UM1CA186712 (1)